EGFR-targeted plasmonic magnetic nanoparticles suppress lung tumor growth by abrogating G2/M cell-cycle arrest and inducing DNA damage

Abstract

Background We have previously demonstrated the epidermal growth factor receptor (EGFR)-targeted hybrid plasmonic magnetic nanoparticles (225-NP) produce a therapeutic effect in human lung cancer cell lines in vitro. In the present study, we investigated the molecular mechanism of 225-NP-mediated antitumor activity both in vitro and in vivo using the EGFR-mutant HCC827 cell line. Methods The growth inhibitory effect of 225-NP on lung tumor cells was determined by cell viability and cell-cycle analysis. Protein expression related to autophagy, apoptosis, and DNA-damage were determined by Western blotting and immunofluorescence. An in vivo efficacy study was conducted using a human lung tumor xenograft mouse model. Results The 225-NP treatment markedly reduced tumor cell viability at 72 hours compared with the cell viability in control treatment groups. Cell-cycle analysis showed the percentage of cells in the G2/M phase was reduced when treated with 225-NP, with a concomitant increase in the number of cells in Sub-G1 phase, indicative of cell death. Western blotting showed LC3B and PARP cleavage, indicating 225-NP-treatment activated both autophagy- and apoptosis-mediated cell death. The 225-NP strongly induced γH2AX and phosphorylated histone H3, markers indicative of DNA damage and mitosis, respectively. Additionally, significant γH2AX foci formation was observed in 225-NP-treated cells compared with control treatment groups, suggesting 225-NP induced cell death by triggering DNA damage. The 225-NP-mediated DNA damage involved abrogation of the G2/M checkpoint by inhibiting BRCA1, Chk1, and phospho-Cdc2/CDK1 protein expression. In vivo therapy studies showed 225-NP treatment reduced EGFR phosphorylation, increased γH2AX foci, and induced tumor cell apoptosis, resulting in suppression of tumor growth. Conclusion The 225-NP treatment induces DNA damage and abrogates G2/M phase of the cell cycle, leading to cellular apoptosis and suppression of lung tumor growth both in vitro and in vivo. Our findings provide a rationale for combining 225-NP with other DNA-damaging agents for achieving enhanced anticancer activity.

DLEU1 contributes to ovarian carcinoma tumourigenesis and development by interacting with miR‐490‐3p and altering CDK1 expression

“…We suggest that DLEU1 affects the expression of its target genes by regulating the expression of miR-490-3p. CDK1, a cell cycle regulator CDK family member, is the key molecule of the ATM-chk2-CDC25-CCNB1/CDK1 pathway that controls the cell cycle [24,25]. Xi et al showed that CDK1 expression is associated with ovarian cancer cell proliferation and can serve as an independent prognostic factor [26].…”

Magnetic nanoparticles as a new approach to improve the efficacy of gene therapy against differentiated human uterine fibroid cells and tumor-initiating stem cells

“…Consequences of MNP treatment included induction of autophagy, apoptosis, and DNA damage which resulted in effective tumor growth inhibition both in vitro and in vivo . This study established proof-of-concept, by demonstrating a novel mechanism of MNP action – its ability to produce antitumor activity in lung cancer cells (68). Using nanoparticles to enhance adenovirus-mediated gene therapy is novel to the field of UFs.…”

Liposome-encapsulated plasmid DNA of telomerase-specific oncolytic adenovirus with stealth effect on the immune system

“…Many kinds of nanomaterials, such as liposomes, micelles, polymers, and metal nanoparticles, have been developed and have contributed greatly to the development of drug delivery systems 17 , 18 . In addition to the above-mentioned Doxil, Abraxane (Celgene, Summit, NJ) is another nanotechnology-based chemotherapeutic agent for malignant tumors, which is a nanoparticle albumin-bound paclitaxel approved for breast cancer, non-small cell lung cancer, and pancreatic cancer by the FDA and for gastric cancer in Japan 19 , 20 .…”